Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PH-762 · 1 trial · 3 indications
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| Sequential escalating doses of PH-762. | EXPERIMENTAL | Escalating doses of PH-762 are to be tested, with an observation period between doses. |
| Name | Type | Description |
|---|---|---|
| PH-762 | DRUG | PH-762 is a potent RNAi molecule targeting PD-1. |
Key Inclusion Criteria: * Histologically confirmed cutaneous squamous cell carcinoma (cSCC), melanoma, or Merkel cell carcinoma, meeting one of the following criteria: * cSCC, resectable local tumors: must be Stage II or lower, amenable to curative resection and in a location where acceptable su...
PH-762 is an investigational small molecule developed by Phio Pharmaceuticals Corp. (ticker PHIO) for the treatment of squamous cell carcinoma of the skin. It is designed to target PD-1 and is being studied as an intratumoral therapy in oncology. PH-762 remains in clinical development and is not approved for commercial use.
PH-762 is being evaluated for the treatment of squamous cell carcinoma of the skin, a type of non-melanoma skin cancer. It is administered intratumorally and is also being studied in related cutaneous carcinomas including malignant melanoma of skin and Merkel cell carcinoma of skin. The drug is investigational and has not been approved for any indication.
PH-762 targets PD-1, a gene that encodes an immune checkpoint protein. By targeting PD-1, PH-762 is intended to modulate the immune response against tumor cells. This mechanism is being investigated in cutaneous carcinomas, including squamous cell carcinoma of the skin.
PH-762 is being developed by Phio Pharmaceuticals Corp., a biopharmaceutical company that trades under the ticker symbol PHIO. The company is advancing PH-762 as an intratumoral small molecule for cutaneous carcinomas, including squamous cell carcinoma of the skin.
PH-762 is in Phase 1 clinical development. A single Phase 1 trial has been completed, evaluating intratumoral PH-762 in patients with cutaneous carcinoma. The drug is investigational and has not received FDA approval for any indication.
PH-762 has been studied in one completed Phase 1 trial, NCT06014086, titled Intratumoral PH-762 for Cutaneous Carcinoma. The trial enrolled 22 participants in the United States and included patients with squamous cell carcinoma of the skin, malignant melanoma of skin, and Merkel cell carcinoma of skin. It was an uncontrolled, non-randomized study.